Trial · NCT06698965
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
NCT06698965, Phase 2, Recruiting, Shanghai Chest Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin. Trials, record NCT06698965. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06698965
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
- NCT number
- NCT06698965
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 52 participants, estimated
- Lead sponsor
- Shanghai Chest Hospital
- Conditions
- Lung Cancer, Small Cell
- Interventions
- Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib
- First posted
- 2024-11-21
- Last updated
- 2024-11-21
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The incidence of grade ≥ 3 neutropenia during chemotherapy treatment | From enrollment to the end of Cycle 6 (each cycle is 21 days) | According to CTCAE5.0 |
| Secondary | The incidence of ≥ grade 3 thrombocytopenia or anemia during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The duration of severe neutropenia in the first treatment cycle | From enrollment to the end of Cycle 1 (each cycle is 21 days) | |
| Secondary | The incidence of febrile neutropenia during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The usage rate of granulocyte colony-stimulating factor (PEG-G-CSF/G-CSF) during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | Disease burden of patients during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | Based on EQ-5D-5L scales scores（The score range is from 5 to 25 points, with higher scores indicating better outcomes） |
| Secondary | The usage rate of erythropoietin (ESA) during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The usage rate of recombinant human interleukin-11 during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The usage rate of thrombopoietin (TPO) during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The usage rate of iron supplement during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06698965
GET https://conductscience.org/api/trials/v1/NCT06698965/registered